Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

Abstract

BACKGROUND The sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been reported to increase both low-density lipoprotein (LDL) and high-density lipoprotein (HDL)-cholesterol (C). This study aimed to determine how SGLT-2 inhibitors affect LDL and HDL-C subspecies. METHODS This single center, open-label, randomized, prospective study included 80… (More)
DOI: 10.1186/s12933-016-0491-5

Topics

6 Figures and Tables

Cite this paper

@inproceedings{Hayashi2017DapagliflozinDS, title={Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin}, author={T. Hayashi and Tomoyasu Fukui and Noriko Nakanishi and Saki Yamamoto and Masako Tomoyasu and Anna Osamura and Makoto Ohara and Takeshi Yamamoto and Yasuki Ito and Tsutomu Hirano}, booktitle={Cardiovascular diabetology}, year={2017} }